Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 crossover study of NBI-827104 in adults with essential tremor
NL-OMON51977Phase 2Active, not recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NBI-827104 in essential tremor (ET), sponsored by Neurocrine Biosciences. Primary endpoints: Change from baseline in postural tremor amplitude, Adverse events and 1 more. Started Apr 2021; status: active, not recruiting.
02
Drugs
NBI-827104
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on NL-OMON51977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51977.